

Mortality trends of gastrointestinal cancers in Iranian population

Mohamad Amin Pourhoseingholi¹, Zeinab Fazeli², Sara Ashtari¹, Fatemeh Sadat Fazeli Bavand-Pour¹

¹Gastroenterology and Liver diseases Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

²Proteomics Research Center, Faculty of Paramedical Science, Shahid Beheshti University of Medical Sciences, Tehran, Iran

ABSTRACT

Aim: The aim of this study was to evaluate the mortality rates and trends from Gastrointestinal (GI) cancer in Iranian population from 1995 to 2003.

Background: Cancer is the third most common cause of death in Iran. Gastrointestinal cancer is the most important causes of mortality due to cancer. The cancer mortality data is important to monitor the effects of screening program, earlier diagnosis, demographic data and other prognostic factors.

Patients and methods: National death Statistic Reported by the Ministry of Health and Medical Education (MOH&ME) from 1995 to 2003, stratified by age group, sex, and cause of death is included in this analysis. Colorectal cancer (CRC) [ICD-9; 153-154], Gastric cancer (GC) [ICD-9; 151], Pancreas cancer (PC) [ICD-9; 25], Esophageal cancer (EC) [ICD-9; C15] and Hepatocellular carcinoma (HCC) [ICD-9; 20] were expressed as the annual mortality rates/100,000, general and/or per gender, and age group.

Results: The cause specific mortality rate of CRC slightly increased during the years under study and for GC and EC showed a sharp increasing. In contrast, the mortality rate of PC decreased slightly during the years under the study. The rate of HCC mortality moderately increased. All mortality rates were higher for male than female.

Conclusion: Our study indicated remarkable increasing trends in mortality of GI cancer in Iran specifically for CRC and GC. Developing for a GC and EC for both primary prevention and early detection programs and providing the facilities for CRC screening, would be the options to control the mortality and burden of GI cancers in the future.

Keywords: Colorectal Cancer, Gastric Cancer, Esophageal Cancer, Pancreas Cancer, Hepatocellular carcinoma.

(Please cite as: **Pourhoseingholi MA, Fazeli Z, Ashtari S, Fazeli Bavand-Pour FS. Mortality trends of gastrointestinal cancers in Iranian population. Gastroenterol Hepatol Bed Bench 2013;6(Suppl. 1): S52-S57.**)

Introduction

Cancer is the third most common cause of death in Iran and annually 30000 of Iranian die due to cancer (1). The gastrointestinal (GI) cancers are the most frequent cancer among Iranian males and second among females (2, 3). Generally, GI cancers account for nearly half of all cancer causes of deaths in Iran (1). According to the cancer

registry program, it is estimated that the majority of the GI cancers occurring in the stomach and the next sites most commonly affected by GI cancers are the colon and rectum (colorectal cancers), esophagus, pancreas and liver (4) and these cancers are the most common gastrointestinal malignancies in Iran (5).

Despite its recent decline, gastric cancer is the fourth most common cancer and the second leading cause of cancer-related death worldwide (6, 7). Iranian data suggested that GC is a fatal

Received: 8 May 2013 Accepted: 18 July 2013

Reprint or Correspondence: Mohamad Amin Pourhoseingholi, PhD. Gastroenterology and Liver diseases Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

E-mail: amin_phg@yahoo.com

cancer in the term of life lost and mortality (8-12) with high burden of hospitalization (3).

Colorectal cancer (CRC) is another public health burden in most industrialized countries (13) and one of the mortal cancers worldwide with economically developed countries having the highest incidence (14).

According to Iranian studies, there is a younger age distribution for CRC compared to Western reports (15, 16).

Esophageal cancer (EC) is one of the most common cancers in the world (17) with very low rates of survival (18). The incidence of esophageal cancer in Iran has variable similar to other high-risk areas of the Asian esophageal cancer belt (2).

Hepatocellular carcinoma (HCC) represents approximately the sixth most prevalent cancer worldwide and due to the poor prognosis it is also the fourth cause of death related to cancer (17). Burden of HCC is not high Iran because most of cases are due to hepatitis B and this infection was less common in Iran than Southeast Asia and Africa (19). Pancreatic cancer (PC) is a fatal cancer which accounts for about 220,000 deaths annually and is the sixth major cause of cancer-related mortality (17, 20). In Iran, pancreas cancer is not rank in the top 10 for newly diagnosed cases (21).

Death statistics are important factor to monitor the effects of screening program, early diagnosis and other prognostic factors (22). So the aim of this study was to evaluate the mortality rates and trends from GI cancers Iranian population during a period of a decade, i.e. from 1995 to 2004.

Methods

National death Statistic Reported by the Ministry of Health and Medical Education (MOH&ME) from 1995 to 2000 (registered death statistics for Iranian population at the Information Technology and Statistic Management Center, MOH&ME) and from 2001 to 2004 (published by MOH&ME) (1, 23,

24) stratified by age group, sex, and cause of death (coded according to the 9th revision of the International Classification of Diseases [ICD-9]) are included in this analysis. GC [ICD-9; 151], CRC [ICD-9; 153-154], EC [ICD-9; C15], HCC [ICD-9; 20] and PC [ICD-10; 25] were expressed as the annual mortality rates/100,000, overall, by sex and by age group (<15, 15-49 and \geq 50 years of age). The populations of Iran in 1995-2004 were estimated by age group and sex using the census from 1996 conducted by Statistics Centre of Iran and its estimation according to population growth rate for years before and after national census (25).

Results

All death records due to GC, CRC, EC, HCC and PC from 1995 to 2004 are included in this study (for HCC and PC just data available from 1999 to 2004).

By adjusting the populations of Iran in the years under study, the mortality rate calculated per 100,000. The highest mortality rate belongs to GC which showed a sharp increasing from 1.68 to 8.78 during the years of study, however a slight decreasing was observed between 2002 and 2004 (Table 1, Figure 1).

Table 1. Crude mortality rate for GI Cancer mortality during the period 1995-2004 per 100,000

	<i>CRC</i>	<i>GC</i>	<i>HCC</i>	<i>EC</i>	<i>PC</i>
1995	0.44	1.68	NA	0.71	NA
1996	0.70	3.04	NA	1.41	NA
1997	0.86	3.38	NA	1.36	NA
1998	1.02	2.29	NA	1.46	NA
1999	1.22	5.70	2.56	1.98	1.16
2000	1.49	6.04	3.04	2.18	1.03
2001	1.69	6.47	3.33	2.10	1.05
2002	2.42	9.86	3.88	3.71	0.89
2003	2.54	9.67	3.76	3.58	0.90
2004	1.39	8.78	3.53	3.35	0.73

Colorectal Cancer (CRC), Gastric Cancer (GC), Hepatocellular Carcinoma (HCC), Esophageal Cancer (EC), Pancreas Cancer (PC), NA:No data available for this year




Figure 1. Trends of GI Cancer mortality during the period 1999-2004 by sex groups (Rate per 100,000)

In addition to this, GC mortality rate was higher for men (Table 2). The crude mortality rate of CRC slightly increased during these years from 0.44 to 2.54 and a little decreased in 2004 (Table 1). There is also increasing trend for EC in this period (Table 1, Figure 1) however, a slight decreasing was observed from 2002 to 2004. The rate was higher for men too (Table 2).

The rate of HCC mortality and moderately increased from 1999 to 2003 and seems to be leveled off in 2004 (Table 2). Besides, the mortality due to HCC for men was high comparing to women

considerably (Table 2).

The mortality rate of pancreatic cancer decreased slightly during the years under the study. It was higher for male and the declining was more for men than women and it seems that pancreatic cancer mortality trend for women was leveled off with slight decreasing from 0.77 in 1999 to 0.57 in 2004 per 100,000 (Table2).

The total rate for all deaths due to GI cancers (merged data from 1999 to 2004) indicated that the mortality was increased from 16.06 per 100000 in 1999 to 19.03 per 100000 in 2003 and slightly decreased in 2004. The rate was higher for men and increased as age increased (Table 3).

Table 3. Mortality rate for total GI Cancer mortality during the period 1995-2004 stratified by sex and age group per 100,000

Year	Age group			Sex group (Male/Female)		Total crud rate
	<15	15-50	>50	M	F	
1999	0.10	3.83	111.5	20.87	11.07	16.06
2000	0.34	3.80	113.84	19.69	11.59	15.72
2001	0.43	3.90	105.96	20.75	13.39	17.15
2002	0.20	4.42	130.13	23.21	15.11	19.28
2003	0.34	4.25	127.53	23.03	14.84	19.03
2004	0.45	4.01	110.65	20.26	12.39	16.41

Table 2. Crude mortality rate for GI Cancer mortality during the period 1995-2004 stratified by sex group per 100,000

	CRC		GC		HCC		EC		PC	
	Female	Male	Female	Male	Female	Male	Female	Male	Female	Male
1995	0.41	0.46	1.18	2.17	NA	NA	0.68	0.73	NA	NA
1996	0.56	0.81	1.03	3.95	NA	NA	1.10	1.70	NA	NA
1997	0.64	1.04	2.29	4.44	NA	NA	1.11	1.61	NA	NA
1998	0.91	1.13	3.22	5.32	NA	NA	1.30	1.61	NA	NA
1999	1.00	1.43	3.97	7.36	1.96	3.13	1.59	2.36	0.77	1.54
2000	1.25	1.73	4.55	7.47	2.66	3.14	1.78	2.55	0.70	1.25
2001	1.52	1.86	4.93	7.49	2.84	3.80	1.81	2.39	0.86	1.22
2002	1.96	2.86	7.27	12.29	3.30	4.43	3.13	4.28	0.64	1.13
2003	1.90	3.15	7.05	12.17	3.22	4.28	3.22	3.92	0.70	1.10
2004	1.23	1.48	6.15	11.30	2.77	4.26	2.74	3.93	0.57	0.89

Colorectal Cancer (CRC), Gastric Cancer (GC), Hepatocellular Carcinoma (HCC), Esophageal Cancer (EC), Pancreas Cancer (PC), NA:No data available for this year

Discussion

The results of this study indicated that the rate of mortality for GI cancers has been increasing or stabilized during the years under study. The GC and EC showing sharp decreased, CRC slightly increased, HCC stabilized and PC decreased. The total deaths due to GI cancer seem to be stabilized according to all GI cancers.

Cancer is still an increasing health problem in Iran and Cancers of GI tract has been reported as the most common fatal cancer in Iran. (3).

Cancers of the gastric, esophagus and colorectal are now the three leading types of cancer found in males, and cancers of the breast, esophagus and gastric in females in some areas of Iran (26). In contrast to our findings, European studies showed that CRC and GC mortality decreased (27, 28). The incidence of GC in Iran is still high (26) and most of patients are diagnosed in a “non curable” stage (10, 29) because the most patients are diagnosed in advanced stage and there is no early detection strategy in Iran to detect the patients in lower stage of disease (11). In the North America, CRC incidence and mortality showed a trend towards declining (7) and its mortality in the European Union was also decreasing (30), however in eastern Europe an increasing incidence and mortality has been registered (31).

The incidence of CRC in Iran is increased remarkable over the last three decades (32, 33). The incidence is still lower in older Iranians; however, it is close in young Iranians and Americans (34) therefore this similarity and the linear increasing trend of its mortality may predicting the higher burden in future (35).

The mortality of Esophagus cancer in some western countries such as France and Italy, have continuously decreased and in others like as UK and US, has gradually increased since 1960 (36). Chinese data and Japanese data revealed that mortality rates for EC are decreasing (36, 37).

Tobacco and alcohol are the risk factors for EC in the world (38, 39). But in Iran it seems that patterns of food and nutrient consumption (including drinking hot tea) and also socio-economic status are playing the main role in high risk area of Iran (40, 41, 42).

The mortality rate of HCC in Iran seems to be reached the plateau. A recent study in southern Iran indicated that the predominant cause for HCC was hepatitis B (43) and this infection was less common in Iran (19). Besides, the mass vaccination program against hepatitis B started in 1993 and reached 94% coverage in 2005 (44) so the impact of vaccination on decreasing the burden of HCC is suppose to be in future decades (19).

The declining trend of pancreatic cancer mortality in Iran is in contrast to western countries such as Germany, US, France and Spain which have reported an increasing trend according to WHO Mortality Database (45). Pancreatic cancer is one of the cancers which are correlated with industrialization and majority of deaths occurred in developed countries (46). Pancreatic cancer is a fatal cancer with low survival. Iranian mortality data suggested that the trend of this fatal cancer is still low and may be leveled off in recent years (47, 48).

A limitation of this study is underestimating of mortality for cancers in Iran due to poor registry (1). There were no registered data for HCC and PC before 1999 and unfortunately after 2004, no completed data were published yet by the Ministry of Health and Medical Education (MOH&ME) in order to update the trend information.

In conclusion, the trend of GI cancer mortality in Iranian population increased in recent years and seems to be leveled off. The access of screening for CRC (49), developing a gastric cancer early detection program (11) and conducting a program to increase general awareness of known and probable risk factors of EC (50, 51), may be helpful to reduce the burden of these fatal cancers in Iranian population.

References

1. Naghavi M. Death report from 23 provinces in Iran. 1st edition. 2004; Ministry of Health and Medical Education ; Tehran.
2. Mosavi-Jarrahi A, Mohagheghi MA. Epidemiology of esophageal cancer in the high-risk population of Iran. *Asian Pac J Cancer Prev* 2006; 7: 375-80.
3. Pourhoseingholi MA, Vahedi M, Moghimi-Dehkordi B, Pourhoseingholi A, Ghafarnejad F, Maserat E, et al. Burden of hospitalization for gastrointestinal tract cancer patients - Results from a cross-sectional study in Tehran. *Asian Pac J Cancer Prev* 2009; 10:107-10.
4. Cancer incidence in the Tehran Metropolita. Second report of the Tehran Population-Based cancer registry, the cancer Institute cancer research centre, 2007.
5. Moghimi-Dehkordi B, Safaee A, Zali MR. Comparison of colorectal and gastric cancer: survival and prognostic factors. *Saudi J Gastroenterol* 2009; 15:18-23.
6. Parkin DM. International variation. *Oncogene* 2004; 23:6329-40.
7. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000: the global picture. *Eur J Cancer* 2001; 37:S4-S66.
8. Pourhoseingholi MA, Hajizadeh E, Moghimi-Dehkordi B, Safaee A, Abadi A, Zali MR. Comparing Cox regression and parametric models for survival of patients with gastric carcinoma. *Asian Pac J Cancer Prev* 2007; 8:412-6.
9. Moghimi-Dehkordi B, Safaee A, Pourhoseingholi MA, Zali MR. Effect of demographic and clinicopathologic factors on prognosis of early gastric cancer in Iran. *Asian Pac J Cancer Prev* 2008; 9:585-8.
10. Pourhoseingholi MA, Moghimi-Dehkordi B, Safaee A, Hajizadeh E, Solhpur A, Zali MR. Prognostic factors in gastric cancer using log-normal censored regression model. *Indian J Med Res* 2009; 129:262-7.
11. Pourhoseingholi MA, Faghihzadeh S, Hajizadeh E, Gatta G, Zali MR, Abadi AR. Trend Analysis of Gastric Cancer and Colorectal Cancer Mortality in Iran, 1995-2003. *Iran J Cancer Prev* 2011; 1:38-43.
12. Pourhoseingholi MA, Faghihzadeh S, Hajizadeh E, Abadi A Bayesian Analysis of Gastric Cancer mortality in Iranian Population. *Gastroenterol Hepatol Bed Bench* 2010;3:15-18.
13. Sonnenberg A, Delcò F, Inadomi JM. Cost-effectiveness of colonoscopy in screening for colorectal cancer. *Ann Intern Med* 2000; 133:573-84.
14. World Health Organization. Cancer Incidence in Five Continents, Vol. 8. Lyon: IARC Press; IARC Scientific Publication, 2002. No. 155.
15. Moghimi-Dehkordi B, Safaee A, Zali MR. Prognostic factors in 1,138 Iranian colorectal cancer patients. *Int J Colorectal Dis* 2008; 23:683-88.
16. Azadeh S, Moghimi-Dehkordi B, Fatemi SR, Pourhoseingholi MA, Ghiasi S, Zali MR. Colorectal cancer in Iran: an epidemiological study. *Asian Pac J Cancer Prev* 2008; 9:123-26.
17. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. *CA Cancer J Clin* 2005; 55:74-108.
18. Polednak AP. Trends in survival for both histologic types of esophageal cancer in US surveillance, epidemiology and end results areas. *Int J Cancer* 2003;105: 98-100.
19. Pourhoseingholi MA, Fazeli Z, Zali MR, Alavian SM. Burden of Hepatocellular Carcinoma in Iran; Bayesian Projection and Trend Analysis *Asian Pac J Cancer Prev* 2010;11:859-62.
20. Lowenfels AB, Maisonneuve P. Risk factors for pancreatic cancer. *J Cell Biochem* 2005;95:649-56.
21. Iranian Annual of National Cancer Registration Report. Ministry of Health and Medical Education, Center for Disease Control & Prevention, Noncommunicable Deputy, Cancer Office, 2008.
22. Burnet NG, Jefferies SJ, Benson RJ, Hunt DP, Treasure FP. Years of life lost (YLL) from cancer is an important measure of population burden--and should be considered when allocating research funds. *Br J Cancer* 2005;92:241-45.
23. Naghavi M. Death report from 18 provinces in Iran. 1st edition. 2002; Ministry of Health and Medical Education, Tehran, Iran.
24. Naghavi M. Death report from 18 provinces in Iran. 1st edition. 2003; Ministry of Health and Medical Education, Tehran, Iran.
25. National Statistics Center, Online Publications at: <http://amar.sci.org.ir/PlanList.aspx>.
26. Sadjadi A, Nouraie M, Mohagheghi MA, Mousavi-Jarrahi A, Malekzadeh R, Donald Maxwell P. Cancer occurrence in Iran in 2002, an international prospective. *Asian Pacific J Cancer Prev* 2005; 6:359-63.
27. Levi F, Lucchini F, La Vecchia C, Negri E. Trends in mortality from cancer in European Union, 1955-94. *Lancet* 1999; 354:742-43.

28. Levi F, Lucchini F, Negri E, Boyle P, La Vecchia C. Cancer mortality in Europe, 1995-1999, and an overview of trends since 1960. *Int J Cancer* 2004; 110:155-69.
29. Moghimi-Dehkordi B, Safaee A, Zali MR. Survival rates and prognosis of gastric cancer using an actuarial life-table method. *Asian Pac J Cancer Prev* 2008; 9:317-21.
30. Fernandez E, La Vecchia C, Gonzalez JR, Lucchini F, Negri E, Levi F. Converging patterns of CR mortality in Europe. *Eur J Cancer* 2005; 41:430-37.
31. Valean S, Mircea PA, Oprea L, Frentiu D, Popescu G, Nagy G, et al. Trends of mortality rates from gastric cancer and colorectal cancer in Romania 1955-2003. *J Gastrointest Liver Dis* 2006; 15:111-15.
32. Center for Disease Control and Prevention, Noncommunicable Deputy Cancer Office. Iranian Annual National Cancer Registration Report 2005 – 2006 [in Persian]. Tehran (Iran): Ministry of Health and Medical Education; 2007.
33. Hosseini SV, Izadpanah A, Yarmohammadi H. Epidemiological changes in colorectal cancer in Shiraz, Iran: 1980–2000. *ANZ J Surg* 2004; 74:547–49.
34. Moradi A, Khayamzadeh M, Guya MM, Mirzaei HR, Salmanian R, Rakhsha A, Akbari ME. Survival of colorectal cancer in Iran. *Asian Pac J Cancer Prev* 2009; 10:583-86.
35. Malekzadeh R, Bishehsari F, Mahdavinia M, Ansari R. Epidemiology and molecular genetics of colorectal cancer in Iran: a review. *Arch Iran Med* 2009; 12:161-19.
36. Qiu D, Kaneko S. Comparison of esophageal cancer mortality in five countries: France, Italy, Japan, UK and USA from the WHO mortality database (1960-2000). *Jpn J Clin Oncol* 2005;35:564-67.
37. Ke L. Mortality and incidence trends from esophagus cancer in selected geographic areas of China circa 1970-90. *Int J Cancer* 2002; 102:271-4.
38. IARC: Tobacco smoke and involuntary smoking. *IARC Monogr Eval Carcinog Risks Hum* 2004;83:1-1438.
39. Corrao G, Bagnardi V, Zambon A, La Vecchia C. A meta-analysis of alcohol consumption and the risk of 15 diseases. *Prev Med* 2004; 38:613-19.
40. Islami F, Kamangar F, Nasrollahzadeh D, Møller H, Boffetta P, Malekzadeh R. Oesophageal cancer in Golestan Province, a high-incidence area in northern Iran - a review. *Eur J Cancer* 2009;45:3156-65.
41. Islami F, Kamangar F, Nasrollahzadeh D, Aghcheli K, Sotoudeh M, Abedi-Ardekani B, et al. Socio-economic status and oesophageal cancer: results from a population-based case-control study in a high-risk area. *Int J Epidemiol* 2009;38:978-88.
42. Islami F, Pourshams A, Nasrollahzadeh D, Kamangar F, Fahimi S, Shakeri R, et al. Tea drinking habits and oesophageal cancer in a high risk area in northern Iran: population based case-control study. *BMJ* 2009; 26;338:b929.
43. Hajiani E, Masjedizadeh R, Hashemi J, Azmi M, Rajabi T. Risk factors for hepatocellular carcinoma in southern Iran. *Saudi Med J* 2005;26:974-77.
44. Alavian SM, Fallahian F, Lankarani KB. The changing epidemiology of viral hepatitis B in Iran. *J Gastrointest Liver Dis* 2007;16:403-406.
45. Katanoda K, Yako-Suketomo H. Comparison of time trends in pancreatic cancer mortality (1990-2006) between countries based on the WHO mortality database. *Jpn J Clin Oncol* 2010;40:601-602.
46. Pisani P, Parkin DM, Bray F, Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. *Int J Cancer* 1999;83:18-29.
47. Pourhoseingholi MA, Pourhoseingholi A, Vahedi M, Ashtari S, Safaee A, Moghimi-Dehkordi B, Zali MR. Pourhoseingholi. Decreased trend of pancreatic cancer mortality in Iran. *Asian Pac J Cancer Prev* 2011;12:153-55.
48. Taghavi A, Fazeli Z, Vahedi M, Baghestani AR, Zali MR, Pourhoseingholi MA. Pancreatic cancer mortality and misclassification--bayesian analysis. *Asian Pac J Cancer Prev* 2011;12:2271-74.
49. Pourhoseingholi MA, Zali MR. Colorectal cancer screening: Time for action in Iran. *World J Gastrointest Oncol* 2012;4:82-83.
50. Pourhoseingholi MA, Abadi A, Faghihzadeh S, Pourhoseingholi A, Vahedi M, Moghimi-Dehkordi B, Safaee A, Zali MR. Bayesian analysis of esophageal cancer mortality in the presence of misclassification. *Ital J Public Health* 2010; 8: 342-47.
51. Pourhoseingholi MA, Fazeli Z, Moghimi-Dehkordi B, Vahedi M, Pourhoseingholi A, Safaee A, et al. Increased oesophageal cancer mortality rate in Iran. *Arab J Gastroenterol* 2012; 13:82-84.